Sibutramine and its cardiovascular profile

International Journal of Obesity

Volumn 26, Issue , 2002, Pages S38-S41

  Narkiewicz, K ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Blood pressure; Heart rate; Hypertension; Sibutramine; Withdrawal criteria

Indexed keywords

SIBUTRAMINE;

BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMORBIDITY; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; OBESITY; PRIORITY JOURNAL; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT PLANNING; VASODILATATION; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; CYCLOBUTANES; HEMODYNAMIC PROCESSES; HUMANS;

EID: 0036955099     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802218     Document Type: Article

References (10)

1. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: 3S–10S.
2. Julius S, Valentini M, Palatini P. Overweight and hypertension: a 2-way street? Hypertension 2000; 35: 807–813.
3. Sharma AM. Sibutramine in overweight=obese hypertensive patients. Int J Obes Relat Metab Disord 2001; 24(Suppl 4): S20–S23.
4. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331–1339.
5. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000; 94: 152–158.
6. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185–2191.
7. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensinconverting enzyme inhibitors. J Hum Hypertens 2002; 16: 5–11.
8. Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002; 16: 13–19.
9. Bérubé-Parent S. Obesity treatment with a progressive clinical tritherapy combining sibutramine and a supervised diet-exercise intervention. Int J Obes Relat Metab Disord 2001; 25(8): 1144–1153.
10. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF, for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119–2125.